Mentice AB (SE:MNTC)
:MNTC
Want to see SE:MNTC full AI Analyst Report?
Top Page
Mentice AB
(MNTC)
Select Model
Select Model
Rating:55Neutral
Price Target:
kr14.50
▲(8.21% Upside)
Action:Reiterated
Date:05/14/26
The score is driven primarily by improving financial performance (revenue and margin rebound, positive operating cash flow) but remains constrained by continued net losses and weak free cash flow consistency. Technicals are moderately supportive with price above major moving averages, while valuation is pressured by the negative P/E.
Positive Factors
Improving profitability trajectory
The combination of a ~40% gross margin, EBITDA turning positive and positive operating cash flow reflects durable improvement in unit economics and operating leverage. Sustained margins and EBITDA expansion support reinvestment in content, R&D and scaling customer success without immediate reliance on external capital.
Negative Factors
Continued net losses
Despite EBITDA improvement, negative operating and net margins indicate earnings have not yet sustainably turned positive. Persistent losses constrain retained earnings, limit capacity for dividend or share buybacks, and require continued focus on margin conversion to secure long-term shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving profitability trajectory
The combination of a ~40% gross margin, EBITDA turning positive and positive operating cash flow reflects durable improvement in unit economics and operating leverage. Sustained margins and EBITDA expansion support reinvestment in content, R&D and scaling customer success without immediate reliance on external capital.
Read all positive factors
Mentice AB (MNTC) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr428.92M
Dividend YieldN/A
Average Volume (3M)19.32K
Price to Earnings (P/E)―
Beta (1Y)0.75
Revenue Growth-4.08%
EPS Growth1.31%
CountrySE
Employees131
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.83
Shares Outstanding28,125,734
10 Day Avg. Volume26,429
30 Day Avg. Volume19,315
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)2.71
Price to Sales (P/S)1.34
P/FCF Ratio-14.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.09
Revenue Forecast (FY)kr309.50M
Mentice AB Business Overview & Revenue Model
Company Description
Mentice AB (publ) provides endovascular simulation solutions to teaching entities, healthcare systems, and medical device manufacturers. The company operates through Medical Device Industry, Healthcare Systems, and Strategic Alliances segments. It...
How the Company Makes Money
Mentice makes money primarily by selling and licensing its simulation and training offerings for endovascular interventions. Key revenue streams include: (1) Sales of simulation systems to healthcare providers and training centers, typically inclu...
Mentice AB Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
72
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 286.96M | 279.09M | 290.33M | 273.61M | 217.95M | 185.06M |
| Gross Profit | 115.68M | -33.06M | 257.25M | 236.38M | 188.94M | 149.92M |
| EBITDA | 7.97M | -1.72M | 18.30M | 28.87M | 266.00K | 1.44M |
| Net Income | -21.30M | -32.33M | -18.42M | -2.82M | -30.66M | -29.19M |
Balance Sheet | ||||||
| Total Assets | 299.56M | 312.02M | 323.90M | 322.53M | 332.98M | 261.90M |
| Cash, Cash Equivalents and Short-Term Investments | 56.22M | 33.38M | 53.59M | 59.12M | 47.28M | 12.70M |
| Total Debt | 15.46M | 26.15M | 9.14M | 9.56M | 16.68M | 14.70M |
| Total Liabilities | 176.20M | 173.65M | 180.24M | 163.55M | 170.34M | 125.02M |
| Stockholders Equity | 123.36M | 138.38M | 143.66M | 158.97M | 162.63M | 136.89M |
Cash Flow | ||||||
| Free Cash Flow | -801.00K | -25.43M | 1.48M | 29.53M | 1.85M | -31.03M |
| Operating Cash Flow | 9.80M | -20.30M | 17.92M | 36.52M | 14.91M | -5.13M |
| Investing Cash Flow | -14.77M | -15.46M | -16.44M | -16.18M | -32.28M | -25.90M |
| Financing Cash Flow | 20.82M | 19.66M | -9.31M | -7.05M | 48.99M | -5.78M |
Mentice AB Technical Analysis
Positive
13.40
Price Trends
13.41
Positive
13.49
Positive
13.04
Positive
Market Momentum
0.45
Negative
72.40
Negative
81.99
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MNTC, the sentiment is Positive. The current price of 13.4 is below the 20-day moving average (MA) of 13.40, below the 50-day MA of 13.41, and above the 200-day MA of 13.04, indicating a bullish trend. The MACD of 0.45 indicates Negative momentum. The RSI at 72.40 is Negative, neither overbought nor oversold. The STOCH value of 81.99 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:MNTC.
Mentice AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | kr1.21B | 19.50 | 6.93% | ― | -8.92% | -8.33% | |
55 Neutral | kr428.92M | -5.61 | -27.25% | ― | -4.08% | 1.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr546.68M | -25.75 | -2.52% | ― | -10.66% | 73.69% | |
46 Neutral | kr128.09M | -4.76 | -61.62% | ― | -29.16% | 44.24% | |
46 Neutral | kr303.30M | -6.53 | -104.38% | ― | 26.25% | 43.03% | |
45 Neutral | kr319.06M | -7.16 | -27.22% | ― | -14.57% | 16.16% |
* Healthcare Sector Average
SE:MNTC
Mentice AB
15.25
0.57
3.87%
SE:CLS.B
Clinical Laserthermia Systems AB Class B
4.11
1.41
51.94%
SE:BACTI.B
Bactiguard Holding AB
15.60
-19.90
-56.06%
SE:CRAD.B
C-Rad AB Class B
35.70
3.50
10.87%
SE:ACARIX
Acarix AB
0.27
0.04
17.90%
SE:BRAIN
BrainCool AB
0.81
-0.71
-46.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.